AIP Antibody (Rabbit mAb) [J10D14]

CatNo: F9223

    Application: Reactivity:
    • Lane 1: Hela, Lane 2: Jurkat, Lane 3: HepG2, Lane 4: Mouse brain
    1/

    当該製品は品切れ状态で、メールアドレスをご教示いただければ、お客様に返信いたします。

    代表番号: 045-509-1970|電子メール:sales@selleck.co.jp

    キーポイント

    WB
    転写条件(ウェット): 200 mA, 60 min

    使用情報

    Dilution
    1:1000 - 1:10000
    Application
    WB
    Source
    Rabbit Monoclonal Antibody
    Reactivity
    Mouse, Rat, Human
    Storage Buffer
    PBS, pH 7.2+50% Glycerol+0.05% BSA+0.01% NaN3
    Storage (from the date of receipt)
    -20°C (avoid freeze-thaw cycles), 2 years
    Predicted MW Observed MW
    38 kDa 38 kDa
    *なぜ予測分子量と実際の分子量が異なるのか?
    下記の原因により、実際の分子量が予測と異なる:タンパク質の翻訳後修飾(リン酸化/糖鎖付加),スプライシングバリアント,イソフォーム,相対的な電荷,ポリマー。
    ポジティブコントロール Mouse brain tissue; Mouse heart tissue; Mouse kidney tissue; Mouse spleen tissue; Rat heart tissue; Rat kidney tissue; Human thymus tissue; C6 cells; RAW 264.7 cells; NIH/3T3 cells; HeLa cells; Jurkat cells; HepG2 cells
    ネガティブコントロール

    プロトコール

    WB
    Experimental Protocol:
     
    Sample preparation
    1. Tissue: Lyse the tissue sample by adding an appropriate volume of ice-cold RIPA/NP-40 Lysis Buffer (containing Protease Inhibitor Cocktail),and homogenize the tissue at a low temperature or lyse it by sonication on ice, then incubate on ice for 30 minutes.
    2. Adherent cell: Aspirate the culture medium and wash the cells with ice-cold PBS twice. Lyse the cells by adding an appropriate volume of RIPA/NP-40 Lysis Buffer (containing Protease Inhibitor Cocktail) , sonicate to lyse the cells, and incubate on ice for 30 minutes.
    3. Suspension cell: Transfer the culture medium to a pre-cooled centrifuge tube. Centrifuge and aspirate the supernatant. Wash the cells with ice-cold PBS twice. Lyse the cells by adding an appropriate volume of RIPA/NP-40 Lysis Buffer (containing Protease Inhibitor Cocktail) , sonicate to lyse the cells, and incubate on ice for 30 minutes.
    4. Place the lysate into a pre-cooled microcentrifuge tube. Centrifuge at 4°C for 15 min. Collect the supernatant;
    5. Remove a small volume of lysate to determine the protein concentration;
    6. Combine the lysate with protein loading buffer. Boil 20 µL sample under 95-100°C for 5 min. Centrifuge for 5 min after cool down on ice.
     
    Electrophoretic separation
    1. According to the concentration of extracted protein, load appropriate amount of protein sample and marker onto SDS-PAGE gels for electrophoresis. Recommended separating gel (lower gel) concentration: 10%. Reference Table for Selecting SDS-PAGE Separation Gel Concentrations
    2. Power up 80V for 30 minutes. Then the power supply is adjusted (110 V~150 V), the Marker is observed, and the electrophoresis can be stopped when the indicator band of the predyed protein Marker where the protein is located is properly separated. (Note that the current should not be too large when electrophoresis, too large current (more than 150 mA) will cause the temperature to rise, affecting the result of running glue. If high currents cannot be avoided, an ice bath can be used to cool the bath.)
     
    Transfer membrane
    1. Take out the converter, soak the clip and consumables in the pre-cooled converter;
    2. Activate PVDF membrane with methanol for 1 min and rinse with transfer buffer;
    3. Install it in the order of "black edge of clip - sponge - filter paper - filter paper - glue -PVDF membrane - filter paper - filter paper - sponge - white edge of clip";
    4. The protein was electrotransferred to PVDF membrane. ( 0.45 µm PVDF membrane is recommended ) Reference Table for Selecting PVDF Membrane Pore Size Specifications
    Recommended conditions for wet transfer: 200 mA, 60 min.
    ( Note that the transfer conditions can be adjusted according to the protein size. For high-molecular-weight proteins, a higher current and longer transfer time are recommended. However, ensure that the transfer tank remains at a low temperature to prevent gel melting.)
     
    Block
    1. After electrotransfer, wash the film with TBST at room temperature for 5 minutes;
    2. Incubate the film in the blocking solution for 1 hour at room temperature;
    3. Wash the film with TBST for 3 times, 5 minutes each time.
     
    Antibody incubation
    1. Use primary antibody dilution buffer to prepare the primary antibody working liquid (recommended dilution ratio for primary antibody 1:1000), gently shake and incubate with the film at 4°C overnight;
    2. Wash the film with TBST 3 times, 5 minutes each time;
    3. Add the secondary antibody to the blocking solution and incubate with the film gently at room temperature for 1 hour;
    4. After incubation, wash the film with TBST 3 times for 5 minutes each time.
     
    Antibody staining
    1. Add the prepared ECL luminescent substrate (or select other color developing substrate according to the second antibody) and mix evenly;
    2. Incubate with the film for 1 minute, remove excess substrate (keep the film moist), wrap with plastic film, and expose in the imaging system.

    Datasheet & SDS

    生物学的記述

    Specificity
    AIP Antibody (Rabbit mAb) [J10D14] detects endogenous levels of total AIP protein.
    タンパク質の局在
    細胞質
    Uniprot ID
    O00170
    Clone
    J10D14
    Synonym(s)
    XAP2, AIP, AH receptor-interacting protein, Aryl-hydrocarbon receptor-interacting protein, HBV X-associated protein 2, Immunophilin homolog ARA9, XAP-2
    Background
    Aryl hydrocarbon receptor–interacting protein (AIP) is an immunophilin-like co‑chaperone that associates with heat shock proteins and nuclear receptors and functions as a regulator of protein stability and signaling, best characterized in the context of the cytoplasmic AHR–AIP–Hsp90 complex and pituitary tumorigenesis. The protein contains an N‑terminal region with coiled-coil/Helix features and a C‑terminal tetratricopeptide repeat (TPR) domain that mediates interaction with Hsp90 and client proteins; these structural elements allow AIP to integrate into multi‑chaperone assemblies that stabilize receptors and signaling molecules in an inactive yet ligand‑responsive state. In the xenobiotic-sensing pathway, AIP forms a core part of the AHR complex, maintaining AHR in the cytoplasm with Hsp90, p23 and XAP2, controlling receptor folding, ligand binding and nuclear translocation, and thereby modulating transcriptional responses to environmental toxins and endogenous ligands. In endocrine tissues, germline loss‑of‑function mutations in AIP cause a pituitary adenoma predisposition syndrome within familial isolated pituitary adenomas (FIPA), where affected individuals develop early‑onset, aggressive macroadenomas that are most often growth hormone- or prolactin‑secreting, and AIP behaves as a tumor suppressor whose reduced function permits uncontrolled pituitary cell proliferation. Functional studies show that overexpression of wild‑type AIP in fibroblast and pituitary cell lines markedly reduces cell proliferation, whereas mutant AIP variants lose this antiproliferative effect, and all examined AIP mutations disrupt interaction with phosphodiesterase‑4A5, linking AIP’s tumor suppressor activity to regulation of cAMP signaling. In normal pituitary tissue, AIP colocalizes specifically with growth hormone and prolactin in secretory vesicles of somatotrophs and lactotrophs, while in sporadic pituitary adenomas AIP expression becomes widespread across tumor types and its subcellular localization shifts, with cytoplasmic rather than vesicular distribution in many adenomas, indicating that altered expression patterns and mislocalization accompany tumor development. Population and cohort studies show that 15–30% of FIPA families and a substantial fraction of apparently sporadic pediatric pituitary adenomas harbor inactivating germline AIP mutations, whereas more than half of such familial cases lack AIP mutations, suggesting genetic heterogeneity in pituitary adenoma predisposition beyond AIP. AIP variants and expression changes also appear in other cancers, and high AIP expression associates with more aggressive disease in colorectal and diffuse large B cell lymphoma, indicating that AIP can act as a tumor suppressor or oncogenic factor in a tissue‑specific manner, consistent with its role as a multi‑chaperone modulator that impacts different signaling networks depending on cellular context.
    References

    技術サポート

    ストックの作り方、阻害剤の保管方法、細胞実験や動物実験の際に注意すべき点など、製品を取扱う時に問い合わせが多かった質問に対しては取扱説明書でお答えしています。

    Handling Instructions

    他に質問がある場合は、お気軽にお問い合わせください。

    * 必須

    大学・企業名を記入してください
    名前を記入してください
    電子メール・アドレスを記入してください 有効なメールアドレスを入力してください
    お問い合わせ内容をご入力ください